Mu and kappa opioids modulate mouse embryonic stem cell-derived neural progenitor differentiation via MAP kinases.
As embryonic stem cell-derived neural progenitors (NPs) have the potential to be used in cell replacement therapy, an understanding of the signaling mechanisms that regulate their terminal differentiation is imperative. In previous studies, we discovered the presence of functional mu opioid receptors (MOR) and kappa opioid receptors (KOR) in mouse embryonic stem cells and NPs. Here, MOR and KOR immunoreactivity was detected in NP-derived oligodendrocytes during three stages of their maturation in vitro. Moreover, we examined the modulation of retinoic acid-induced NP differentiation to astrocytes and neurons by mu, [D-ala(2), mephe(4), gly-ol(5)] enkephalin, or kappa, U69, 593, opioids. Both opioid agonists inhibited NP-derived neurogenesis and astrogenesis via their corresponding receptors as determined by immunocytochemistry. By administering selective inhibitors, we found that opioid inhibition of NP-derived astrogenesis was driven via extracellular-signal regulated kinase (ERK), while the p38 mitogen-activated protein kinase pathway was implicated in opioid attenuation of neurogenesis. In addition, mu and kappa opioids stimulated oligodendrogenesis from NP-derived NG2(+) oligodendrocyte progenitors via both ERK and p38 signaling pathways. Accordingly, both opioids induced ERK phosphorylation in NG2(+) cells. These results indicate that small molecules, such as MOR and KOR agonists may play a modulatory role in NP terminal differentiation.
Hahn
Jason W
JW
EA Doisy Department of Biochemistry and Molecular Biology, St. Louis University School of Medicine, St Louis, Missouri 63104, USA.
Jagwani
Shana
S
Kim
Eunhae
E
Rendell
Victoria R
VR
He
Joy
J
Ezerskiy
Lubov A
LA
Wesselschmidt
Robin
R
Coscia
Carmine J
CJ
Belcheva
Mariana M
MM
D000701:Analgesics, Opioid / Q000494:pharmacology; D000818:Animals; D000941:Antigens / Q000378:metabolism; D044482:Benzeneacetamides / Q000494:pharmacology; D002454:Cell Differentiation / Q000187:drug effects / Q000502:physiology*; D002478:Cells, Cultured; D004347:Drug Interactions; D004622:Embryo, Mammalian; D053595:Embryonic Stem Cells / Q000187:drug effects / Q000502:physiology*; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)- / Q000494:pharmacology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005904:Glial Fibrillary Acidic Protein / Q000378:metabolism; D051379:Mice; D020929:Mitogen-Activated Protein Kinase Kinases / Q000378:metabolism*; D009271:Naltrexone / Q000031:analogs & derivatives / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D009836:Oligodendroglia / Q000187:drug effects / Q000502:physiology; D010455:Peptides / Q000494:pharmacology; D011509:Proteoglycans / Q000378:metabolism; D011759:Pyrrolidines / Q000494:pharmacology; D017473:Receptors, Opioid, kappa / Q000819:agonists / Q000378:metabolism*; D017450:Receptors, Opioid, mu / Q000037:antagonists & inhibitors / Q000378:metabolism*; D013997:Time Factors; D014212:Tretinoin / Q000494:pharmacology; D014404:Tubulin / Q000378:metabolism; D000099216:Chondroitin Sulfate Proteoglycan 4
D000701:Analgesics, Opioid; D000941:Antigens; D044482:Benzeneacetamides; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; D004791:Enzyme Inhibitors; D005904:Glial Fibrillary Acidic Protein; D020929:Mitogen-Activated Protein Kinase Kinases; D009271:Naltrexone; D009292:Narcotic Antagonists; D010455:Peptides; D011509:Proteoglycans; D011759:Pyrrolidines; D017473:Receptors, Opioid, kappa; D017450:Receptors, Opioid, mu; D014212:Tretinoin; D014404:Tubulin; D000099216:Chondroitin Sulfate Proteoglycan 4; C462941:beta3 tubulin, mouse; C051844:norbinaltorphimine; C009862:connective tissue-activating peptide; C045444:U 69593